BIIB037: Phase Ib started

Biogen Idec disclosed in its 3Q12 earnings that during the quarter it began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate multiple doses of IV BIIB037 in about 120 patients with ...